Evogene Ltd. (EVGN)

$0.7602

-0.01 (-1.27%)
Rating:
Recommendation:
Buy
Symbol EVGN
Price $0.7602
Beta 0.922
Volume Avg. 0.16M
Market Cap 31.311M
Shares () -
52 Week Range 0.7-3.58
1y Target Est -
DCF Unlevered EVGN DCF ->
DCF Levered EVGN LDCF ->
ROE -44.00% Strong Sell
ROA -36.42% Strong Sell
Operating Margin -
Debt / Equity 23.85% Neutral
P/E -
P/B 0.58 Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest EVGN news


Mr. Ofer Haviv
Healthcare
Biotechnology
NASDAQ Global Market

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through big data and artificial intelligence, designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules, and genetic elements. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer; and through its subsidiary, Canonic Ltd., has a collaboration agreement with Cannbit Ltd. for the development of novel medical cannabis products. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.